About Ascendo
Most checkpoint therapies target the adaptive immune system — and most tumors find a way to resist them. Ascendo takes a different approach: we target CD11b, a novel checkpoint , to remodel the tumor microenvironment from the inside out.
By activating the innate immune system’s own soldiers, we aim to overcome resistance where other therapies fail — and restore immune balance in autoimmune diseases.
ONE
Phase I ASD141 clinical trials are ongoing
TWO
First-in-class pipeline assets
THREE+
Combination therapy potential
(anti-PD1, anti-CTLA4, and more)
Our Mission
To transform treatment outcomes for patients who have exhausted existing options by targeting the innate immune system’s untapped potential.
We are building a platform anchored in the TLT-1/CD11b checkpoint axis, with applications across solid tumor oncology and immune-mediated diseases. Our pipeline comprises one clinical-stage and one preclinical program, designed for deployment alone or in combination with established therapies.
Breakthrough Science
Why the Innate Immune System?
The adaptive immune system — targeted by PD-1 and CTLA-4 therapies — has been the focus of a decade of innovation. Yet over 60% of solid tumor patients do not respond to these treatments.
The innate immune system is the body’s first responder. It patrols, detects, and coordinates the broader immune attack. But in many tumors, a newly discovered molecule called TLT-1 hijacks this system — suppressing the innate immune cells before they can act.
ASD141 blocks TLT-1, releasing this suppression and restoring the innate immune system’s ability to fight back.
Our Team
Built by Leaders Who Have Done This Before
Our leadership team brings decades of experience from global pharmaceutical companies — including Bayer, Takeda, and Bristol-Myers Squibb — combined with deep roots in Taiwan’s clinical and academic research community.
About Us
